---
title: CD19-Targeted CAR T Cells in Haematologic malignancies
layout: post
---

Speaker: Jae Park, MD / Memorial Sloan Kettering Cancer Center | Specialized in ALL CLL NHL

## CD19-Targeted CAR T cells

### Contents

![Gen of 19-28z CAR](http://media4.asco.org/156/9447/110503/110503_video_pvhr.jpg)

* Ab + T cell receptor -> chimeric
* MHC presentation해서 보는게 아니라 Ab처럼 binding하지만 Action은 T cell
* 두개를 합친것. 어떻게 clinic에 사용할 것인가?
* Stable expression할 수 있다.


![Process](https://www.mskcc.org/sites/default/files/styles/large/public/node/39453/image/msk402-cartcell-infographic327.jpg)
https://www.mskcc.org/blog/car-t-cell-therapy-growing-area-research

* Average 60%정도 replication하는 동안은 CAR expression.
* Tumor antigen을 CAR T Cell이 보게 되면서 죽이게 된다.
* Target selection
  * 가장 중요한 것.
  * Protein 등 - tumor specific target인 것이 중요하다.
  * 어떻게 하면 on-target, off-target toxicity를 줄일 수 있을까? off-target, off-target toxicity 줄여야함.
* CD19 and other B cell markers (Stem cells - mature B)
* Normal B cell -> not tumor specific함.
* Signal 1만 막아. Signal2 - CD28, 4-1BB, OX-40 | signal 2가 없으면 anergic - First gen CAR에서는 실패. 2nd gen CAR는 CD28, 4-1BB, OX40
* 3rd gen CAR에서는 임상에서 많이 사용되지는 않는다.

![CAR generation](http://d3md5dngttnvbj.cloudfront.net/content/bloodjournal/125/26/4017/F1.large.jpg)

* Cell production - T cell expansion by dynabeads - 19-28z+ vector와 T cell을 섞어줌. 19-28z+ transduced T cells | CTCEF
* GVHD minimal risk
* ALL - CLL과 다르게 proliferation 빠르다.
* Relapsed ALL은 Px - poor
* Post-CAR T cell infusion
* No cure. 5년정도 F/U
* Clinical Trial
* 4/18 relapse
* Overall survival - relapse하긴 하나
* Murine - T cell - Flow cytometry통해서.
* cytokine release syndrome
* Tc 얼마나 last하는가는 key question
* 어느정도 lasting하는가? - NEJM 2014 - Maude
  * 소아라서 Quality가 다를 수 있는 확률이 있어.
* CRS - fever, hypotension, resp insufficiency - 7일정도
* Neurological changes - delirium, global encephalopathy, aphasia, seizure-like activities/seizure
* disease burden 많으면 severe CRS - correlation이 있다.
* CRP - IL-6 release 높아져.
  * [Tocilizumab](https://en.wikipedia.org/wiki/Tocilizumab )
    * humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
  * Steroid

### Summary
* High CR rates can be achieved in both adults and children with R/R B-ALL
* Durable response - no subsequent allo-SCT
* CRS - mc AE a/w CD19 CAR T cells - toci, steroid
* Neurotoxicity - difficult

### Additional comments
* The hostile Tumor microinvironment
* Armored CARs
  * genetic modification - IL12, CD40L
  * PD-1 K/O할수도 있고..
* IL-12
  * IL-12 pro-inflammatory - IV infusion힘들어.
  * IL-12 secretion-> NK cells & Anergic TIL ->
* CD40L
  * Armored CD40L CAR

### For the future
* Less cumbersome, 3rd party, 더 강한 Tc, solid tumor에서 적용,

### Conclusions
* Autologous CD19-Targeted
* High response rate이지만 perfect하지 않음
* 왜 resistance일어나는지?
* CLL, ALL 다른점 무엇인지?
* heme malignancies-> applicability 있는지? solid tumor로 갈수 있을지?
* target selection

### My Question
Dynabeads를 통해 polyclonal activation된 후 filter할 수 없나?

### Questions
* Car T cell in CSF - Yes
* 41BB PD-1

![enter image description here](http://www.danafarberbostonchildrens.org/uploadedimages/content/page_content/news/2015/dfc_7706_car_t-cell_infographic_branded-2.jpg)

### Reference
* Park J. et al. ASH 2015, Abstract 682
* Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. Jae Hong Park MD
http://meetinglibrary.asco.org/content/110503?media=vm
